Compare Amylx Pharmaceuticals Inc (AMLX) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Church & Dwight Co., Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.26 (market cap $1.98B), while Church & Dwight Co., Inc. trades at $96.24 (market cap $22.83B). The key difference: Church & Dwight Co., Inc. is far larger — about 11.5× Amylx Pharmaceuticals Inc's market cap, and Church & Dwight Co., Inc. pays a 1.28% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CHD | |
|---|---|---|
Market Cap | $1.98B | $22.83B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $105.26 |
52-Week Low | $7.64 | $81.60 |
Enterprise Value | $1.70B | $24.53B |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Church & Dwight (CHD) trades at $96.36, up 0.72% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 adjusted EPS of $0.95, exceeding expectations, driven by 5% organic sales growth. Recent acquisition of Miss Mouth's brand for $325 million aims to strengthen its fabric care portfolio. Cash flow trends show a net outflow in 2025, though operating cash flow remains robust at $1.22 billion.
Outlook remains positive with a consensus price target of $101.33, implying 5% upside, supported by strong analyst sentiment (53% buy ratings). Risks include margin pressure from inflation and competitive threats in consumer staples. The stock's valuation at 31.7x P/E requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
